Solventum (NYSE:SOLV) Given New $105.00 Price Target at Piper Sandler

Solventum (NYSE:SOLV) had its price target increased by Piper Sandler from $92.00 to $105.00 in a report released on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target indicates a potential upside of 25.74% from the stock’s current price.

Several other research firms have also recently weighed in on SOLV. Stifel Nicolaus upped their target price on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday. Wedbush lifted their target price on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday. KeyCorp increased their target price on shares of Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday. Wells Fargo & Company reduced their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Finally, UBS Group reiterated a “buy” rating and set a $101.00 price objective on shares of Solventum in a research report on Thursday. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $91.64.

Solventum Stock Performance

NYSE:SOLV traded down $3.96 on Thursday, hitting $83.50. The company’s stock had a trading volume of 813,693 shares, compared to its average volume of 1,409,545. Solventum has a one year low of $62.38 and a one year high of $90.00. The firm has a market capitalization of $14.46 billion, a P/E ratio of 10.24, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60. The stock has a fifty day moving average of $79.09 and a two-hundred day moving average of $74.36. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $1.91 by $0.64. The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company’s quarterly revenue was up 2.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Research analysts predict that Solventum will post 6.58 earnings per share for the current year.

Institutional Trading of Solventum

Several institutional investors have recently modified their holdings of the business. CrossGen Wealth LLC acquired a new position in Solventum during the 4th quarter worth about $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum in the third quarter worth approximately $25,000. JNBA Financial Advisors boosted its holdings in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after acquiring an additional 228 shares during the last quarter. CYBER HORNET ETFs LLC acquired a new stake in Solventum during the 2nd quarter valued at approximately $28,000. Finally, Modus Advisors LLC bought a new position in Solventum during the 4th quarter worth approximately $30,000.

Solventum News Roundup

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Quarterly earnings and revenue exceeded expectations. Solventum reported second-quarter adjusted EPS of $2.55, well above the $1.91 consensus and up from $1.69 a year earlier. Revenue reached $2.21 billion versus estimates of $2.15 billion, while organic sales increased 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its 2026 outlook. Solventum increased full-year adjusted EPS guidance to $7.10-$7.20, above the approximately $6.55 analyst consensus, and also raised its expectations for organic sales growth and free cash flow. Solventum Raises 2026 EPS Guidance
• Positive Sentiment: Analyst sentiment improved. Stifel Nicolaus raised its price target from $90 to $100 and upgraded Solventum to “buy,” implying approximately 18.9% potential upside from the cited price. This supports the view that the earnings beat and higher guidance could improve the company’s valuation. Benzinga Analyst Update
• Neutral Sentiment: Solventum plans to separate its Health Information Systems business. The company says the move will create a more focused MedTech company, allow the healthcare software business to pursue its own growth strategy and potentially unlock shareholder value. However, the separation will require execution and could create near-term uncertainty, particularly amid activist pressure to divest the business. Solventum to Separate Healthcare Software Business

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.